Evidence map›Paper›PMID 39735151›Full record

ReviewCureus2024

Revolutionizing Acute Stroke Care: A Review of Food and Drug Administration-Approved Software as Medical Devices for Stroke Triage.

Mahdi Haq, Mohamed Derhab, Reeda Saeed, Hasan Khan, Muhammad Mushhood Ur Rehman

Abstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mahdi HaqNeurology, NeuroCareAI, Dallas, USA.
Mohamed DerhabNeurology, Mayo Clinic, Rochester, USA.
Reeda SaeedNeurology, NeuroCareAI, Dallas, USA.
Hasan KhanNeurology, NeuroCareAI, Dallas, USA.
Muhammad Mushhood Ur RehmanNeurology, NeuroCareAI, Dallas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke remains a critical global health challenge, with ischemic stroke comprising most cases and necessitating rapid, effective treatment to improve patient outcomes. This review explores the integration of artificial intelligence (AI) and machine learning into medical devices for stroke triaging, highlighting their impact on reducing notification times, latency in care, and health disparities. By analyzing Food and Drug Administration-approved AI-enabled devices under the "Radiological computer-assisted triage and notification software" regulation category, we assess their sensitivity, specificity, and time-to-notification as the measure of their overall effectiveness in clinical settings. The review identifies 29 such devices, examining their technological capabilities, notification methods, and performance metrics. Key findings provide insights into the potential of AI in enhancing diagnostic accuracy, expediting treatment, and addressing health inequalities. Despite the promising advances, challenges remain in the regulatory landscape and real-world application of these technologies. Future directions emphasize the need for comprehensive clinical trials and deeper algorithmic insights. Collaborative efforts among technology developers, healthcare providers, and policymakers are essential for the successful integration of AI in stroke care to ensure improved patient outcomes and equitable access to advanced medical technologies.

Indexed as

artificial intelligence (ai)fda-approved medical deviceshealth equitymachine learning (ml)stroke triage

Identifiers

PMID39735151
PMCPMC11681945

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.